FCCC LOGO Faculty Publications
Adams SF , Levine DA , Cadungog MG , Hammond R , Facciabene A , Olvera N , Rubin SC , Boyd J , Gimotty PA , Coukos G
Intraepithelial T Cells and Tumor Proliferation
Cancer. 2009 Jul;115(13) :2891-2902
PMCID: PMC2754811   
Back to previous list
Abstract
BACKGROUND: The aim of the study was to determine whether tumor-infiltrating lymphocytes and/or tumor mitotic activity could identify subgroups of patients with advanced serous epithelial ovarian cancer who would maximally benefit from aggressive surgical cytoreduction. METHODS: Snap-frozen specimens from 134 consecutive patients with stage III or IV serous or poorly differentiated ovarian adenocarcinoma undergoing primary debulking surgery from a single US institution were characterized based on CD3(+), CD8(+), FoxP3(+) tumor-infiltrating lymphocytes, and Ki67 expression. Kaplan-Meier survival curves were estimated and compared using a log-rank statistic. A multivariate Cox model was used to estimate adjusted hazard ratios. Interactions were modeled using recursive partitioning based on maximal prognostic differentiation. RESULTS: Brisk intraepithelial CD8+ cells (P = .035) and low Ki67 expression (P = .042) portended prolonged survival. The T-cell infiltration was more likely to occur in tumors with high proliferation index. Patients whose tumors exhibited low Ki67 expression and high intraepithelial CD8+ frequency had a 5-year survival rate of 73.3%. Patients with aggressive tumor behavior, that is, whose tumors exhibited low frequency of intraepithelial CD8+ T cells or high Ki67 expression were more likely to draw benefit from aggressive surgical cytoreduction. Survival was similar for patients with brisk CD8+ T cells who had optimal or suboptimal debulking. Likewise, survival was similar for patients with low Ki67 expression who had optimal or suboptimal debulking. CONCLUSIONS: For the first time, these novel interactions of T cells, tumor proliferation index, and surgical treatment reveal that biological prognosticators may be useful for surgical decision making in ovarian cancer. Cancer 2009;115:2891-902. (C) 2009 American Cancer Society.
Notes
Adams, Sarah F. Levine, Douglas A. Cadungog, Mark G. Hammond, Rachel Facciabene, Andrea Olvera, Narciso Rubin, Stephen C. Boyd, Jeff Gimotty, Phyllis A. Coukos, George JOHN WILEY & SONS INC 459DL